A simplified risk scoring system for predicting high-risk groups in gene expression tests for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, and node-positive breast cancer.
Kwang Hyun YoonSuk-Jun LeeYujin KimJee Hyun AhnJee Ye KimHyung Seok ParkSeung-Il KimSeho ParkPublished in: Annals of surgical treatment and research (2023)
The high GET risk results can be predicted using traditional clinicopathological factors: tumor size, progesterone receptor, histological grade, HER2, and Ki-67. These results will be useful for treatment decision-making among clinically high-risk patients with HR-positive/HER2-negative and node-positive disease, helping to identify patients to whom the GET assay may not apply.
Keyphrases
- estrogen receptor
- epidermal growth factor receptor
- gene expression
- positive breast cancer
- end stage renal disease
- decision making
- lymph node
- tyrosine kinase
- ejection fraction
- newly diagnosed
- endothelial cells
- advanced non small cell lung cancer
- dna methylation
- peritoneal dialysis
- prognostic factors
- pluripotent stem cells
- binding protein